BioSpace News Archive

The global heart valve devices market features a fairly fragmented landscape, notes Transparency Market Research.

The global Physician Office Laboratory Market has been expanding substantially over the last few years.

Eurofins Technologies, a supplier of test kits and systems for laboratory analyses, announces that its ELISA assay for the detection of gluten, SENSISpec Ingezim Gluten R5, has been granted AOAC Research Institute Performance Tested MethodsSM status for use with gluten free bread, oat flour and stainless steel surfaces.

Hua Medicine, a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, announced topline results from SEED, the first Phase III trial with dorzagliatin.

Upjohn Inc., a wholly-owned subsidiary of Pfizer Inc., Upjohn Finance B.V., a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V. announced the pricing of a private offering of $7.45 billion aggregate principal amount of Newco’s senior, U.S. dollar-denominated notes and a private offering of €3.60 billion aggregate principal amount of Finco’s senior, euro-denominated notes

CareDx congratulates C-Path’s Transplant Therapeutics Consortium on utilizing iBox to streamline the development of novel transplant drugs

Aims to Inform use of Minimal Residual Disease (MRD) Monitoring in Clinical Trial Protocols and Future Therapy Optimization

BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it has entered into a collaboration agreement with Johns Hopkins University to support the translation of academic innovations in genetically driven diseases with a goal of clinical development and potential commercialization to reach patients in need. “We are privileged to establish a framework for collaborat

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the U.S. Food and Drug Administration (“FDA” or the “agency”) has granted rare pediatric disease designation for nedosiran, an investigational RNAi therapy being developed as a once-monthly treatment for primary hyperoxaluria (PH). PH

Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer, and Marc Schegerin, M.D., chief financial officer and chief operating officer, are scheduled to make a presentation at the BMO 2020 Prescriptions for Success Healthcare Virtual Confe